Document Detail

Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension.
MedLine Citation:
PMID:  3545477     Owner:  NLM     Status:  MEDLINE    
Two multicenter, double-blind, randomized studies were performed to determine the antihypertensive efficacy and effects on laboratory values of a new, shorter-acting formulation of metolazone in patients with mild to moderate hypertension. After baseline placebo-control periods, 105 patients were randomly assigned to receive single daily doses of either placebo or 0.5, 1.0, or 2.0 mg of the new formulation of metolazone for six weeks in one study, and 164 patients were randomized to receive 0.5, 1.0, or 2.0 mg of the new formulation of metolazone or 2.5 mg of the older, long-acting metolazone in the other. Mean blood pressure reductions in all three metolazone groups were statistically and clinically significant. Blood pressures of 51% to 58% of patients in the 0.5-mg metolazone group were controlled (diastolic blood pressure less than 90 or a fall of greater than or equal to 10 mmHg from baseline). Reductions in mean serum potassium levels were dose-related. We conclude that 0.5 mg of metolazone is safe and effective therapy for hypertension; it will significantly reduce systolic and diastolic blood pressure and minimizes changes in laboratory test values.
C L Curry; S M Janda; R Harris; J H MacKay; C A Nugent; J Ryan; H Schnaper; J Schoenberger
Related Documents :
1971027 - Efficacy of terazosin in the treatment of essential hypertension in blacks.
20823377 - Effects on peripheral and central blood pressure of cocoa with natural or high-dose the...
2968267 - A double-blind and cross-over comparison of once daily doxazosin and placebo with stead...
3365327 - Double-blind versus deceptive administration of a placebo.
9321897 - Skin sympathetic outflow during head-down neck flexion in humans.
6629947 - Pulmonary hemodynamics and gas exchange properties during progressive edema.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical therapeutics     Volume:  9     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  1986  
Date Detail:
Created Date:  1987-04-01     Completed Date:  1987-04-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  47-62     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Clinical Trials as Topic
Diuretics / administration & dosage*
Double-Blind Method
Hypertension / blood,  drug therapy*
Metolazone / administration & dosage*,  adverse effects
Middle Aged
Potassium / blood
Reg. No./Substance:
0/Diuretics; 17560-51-9/Metolazone; 7440-09-7/Potassium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ceftazidime versus tobramycin plus ticarcillin in the treatment of soft-tissue infections.
Next Document:  A double sequential immunofluorescence method demonstrating the co-localization of urotensins I and ...